Top Markets
#1 Pleasing Gold Pleasing Gold +1,049.05%
#2 PulseChain PulseChain +56.20%
#3 BOOK OF MEME BOOK OF MEME +39.77%
#4 DogBull DogBull +36.97%
#5 Ontology Gas Ontology Gas +31.77%
#6 Unit Pump Unit Pump +21.94%
#7 Pump.fun Pump.fun +21.94%
#8 Neiro Neiro +21.70%
#9 Collect on Fanable Collect on Fanable +19.20%
#10 rsERG rsERG +17.92%
Coin of the day
Pleasing Gold Pleasing Gold
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Cytocom, Inc. Cytocom, Inc.

Cytocom, Inc.

CBLI
Rang in aandelen #27147
Cleveland BioLabs, Inc. functions as a biopharmaceutical firm, specializing in... Cleveland BioLabs, Inc. functions as a biopharmaceutical firm, specializing in the discovery and advancement of therapeutic drugs. Based in Buffalo, New York, the organization maintains a modest workforce of 15 full-time employees. Its primary objective involves pioneering methods to stimulate the body's immune defenses to tackle significant medical challenges. A core component of its work is a platform utilizing Toll-like immune receptor activators, which demonstrates utility in both alleviating radiation-induced damage and in the field of immuno-oncology. The most advanced therapeutic candidate in its pipeline is Entolimod, an immune-stimulating compound currently under development as a protective measure against radiation exposure and as an immunotherapy for various cancers and other indications. The company's portfolio also encompasses other promising products, including CBLB612, Mobilan, and CBL0137. CBLB612 is formulated from a natural stimulant that targets a specific component of the innate immune system: the heterodimeric receptor formed by toll-like receptors 2 (TLR2) and 6 (TLR6). Mobilan is a recombinant, non-replicating adenovirus engineered to induce the expression of TLR5 and its corresponding agonistic ligand. Lastly, CBL0137 is a small molecule characterized by a multi-faceted mechanism of action, suggesting its potential effectiveness across diverse forms of cancer.
Aandeelprijs
$3.17
Laatst gesynchroniseerd: 2021-08-31
Marktkapitalisatie
$34.83M
Verandering (1 dag)
-7.31%
Verandering (1 jaar)
0.00%
Land
US
Handel Cytocom, Inc. (CBLI)

Categorie

Healthcare
Winst voor Cytocom, Inc. (CBLI)
Winst in 2026 TTM: 0
Volgens de meest recente financiële verslagen van Cytocom, Inc. bedraagt de huidige winst van het bedrijf 0. In 2026 behaalde het bedrijf een winst van 0, gelijk aan de winst van 2026, die 0 bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Cytocom, Inc. van 2026 tot 2026
Winst aan het einde van elk jaar
Jaar Winst Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Winst van vergelijkbare bedrijven of concurrenten
Bedrijf Winst Winstverschil Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH